Oxfordhsire based nanotechnology company Xerion Healthcare has appointed Professor Justin Stebbing as chairman to drive the company forward as it looks to progress from pre-clinical to patient trials with the aim of increasing quality and length of life of cancer suffers. An internationally renowned oncology expert, Justin has published over 600 peer-reviewed papers, is a fellow of the Royal College of Physicians and the Royal College of Pathologists, and sits on the advisory Boards of a number of international cancer committees.
